Vaccinia Virus anticorps (FITC)

N° du produit ABIN112853

Détail du produit anti-Vaccinia Virus anticorps (FITC)

Antigène: Vaccinia Virus (VACV) (Vaccina Virus (VACV))

Reactivité: Vaccinia Virus (VACV)

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Vaccinia Virus est conjugé à/à la FITC

Application: Immunofluorescence (IF), Enzyme Immunoassay (EIA), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: Affinity Chromatography.

Immunogène: Lister Strain (mixture of virions and infected cell polypeptides).

Information d'application

Indications d'application: Flow Cytometry: 1/50. ELISA and Immunofluorescence: Direct FA staining of target antigens in a permissive tissueculture system. A starting range of 1/10-1/50 is suggested. Acetone fixation of the antigen source is recommended prior to staining.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 4-5 mg/mL (OD280 nm, E0.1% = 1.4)

Buffer: 0.01 M PBS, pH 7.2, 0.09 % Sodium Azide, 10 mg/mL BSA

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing. This product is photosensitive and should be protected from light

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur Vaccinia Virus

Antigène: Vaccinia Virus (VACV) (Vaccina Virus (VACV))

Autre désignation: Vaccinia Virus (VACV Produits)

Classe de substances: Virus

Sujet: Vaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As Vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During Vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize Vaccinia virus infection and enable identification other viral and cellular proteins which participate in the Vaccinia virus entry process.